Aktieanalys

XVIVO: Stepping up the pace during 2024 - Redeye

Redeye 25 Jan 08:51

XVIVO delivers a soft 12% organic growth in the last quarter of 2023 (based on CER excluding acquisition support). The main positive is the gross margins in a quarter with slower organic growth combined with investments in the commercial team. The adjusted EBITDA is also on the soft side. The main sales deviation is a quarter with softer Thoracic support (11% organic growth in Q4). We can expect XVIVO to increase the supply capacity and the commercial US team during 2024. As a result we XVIVO to gain momentum as 2024 proceeds. We expect a negative share price reaction compared with the regional equity market of some 3-5% as a result and we look forward to more details from the call later today and more details from XVIVO regarding the outlook.

Länk till analysen i sin helhet: https://www.redeye.se/research/972226/xvivo-stepping-up-the-pace-during-2024?utm_source=finwire&utm_medium=RSS

Börskollens app – Högt betyg ⭐⭐⭐⭐⭐ och 250.000 nedladdningar

Ladda hem

Vårt nyhetsbrev – Utvalda börsnyheter och heta investeringscase varje vecka

Prenumerera

Nyheter om Xvivo Perfusion

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!